Home | Publications | Management / Strategy place holder
place holder place holder

Management / Strategy

Pharmaceutical Outsourcing Opportunities Post Launch

Contract Manufacturing, and Sales and Marketing,2nd Edition

Publication Date   September 2006
Publisher   Kalorama Information
Product Type   Report
Pages   200
ISBN Number   not applicable
Product Code   KAL047
Ask a question about this product?

Price £1,970.00

approximately: $3,478 | €2,498

Summary


This completely updated edition of this comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including:

  • Point-of-Care
  • Clinical Chemistry
  • Immunoassays
  • Molecular Assays
  • Hematology
  • Coagulation
  • Microbiology and Virology
  • Blood Banking
  • Histology and Cytology

Market size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2010.

This new 1,000-page edition greatly expands coverage of the field and tracks the most important developments. Expanded or added in this edition are sections on:

  • the movement toward POC and decentralization in lab medicine
  • miniaturization and molecularization of devices
  • geo-economic and demographic influences on markets
  • non-invasive sampling
  • greatly expanded market data on PGx and SNP testing
  • revamped segmentation for clinical chemistry to include workstations and immunoanalyzers
  • more information about more immunoassays
  • the renewed interest in microbiology/virology based on resistance and the re-emergence of serious hospital- and community-based organisms
  • world blood banking developments
  • expanded sections on histology/cytology developments including emerging areas such as tissue microarrays, circulating tumor cells, and genomics-fueled innovation.

In addition, there are now profiles of more than established and emerging players in IVD with profiles of more than 421 companies, from the top tier to emerging and niche competitors to watch.

Content


  • Chapter One: Executive Summary
    • Scope and Methodology
    • Size and Growth of the Market
    • Issues and Trends Affecting Market
    • Leading Competitors
  • Chapter Two: Introduction
    • History and Growth of the Cancer Treatment Market
    • Traditional Treatment
    • Immunomodulator Discovery
    • Immuonologic Approaches to Cancer
    • Demographics and Statistics
  • Chapter Three: Current Immunomodulators Available For Cancer Treatment
    • Cancers with Available Products
    • Kidney Cancer
    • Leukemia
    • Lymphoma
    • Description of Products
    • Interleukins
    • Interferons
    • Tumor Necrosis Factor
    • Growth Factors
    • Market Size and Growth
    • Competitive Analysis
  • Chapter Four: Emerging Immunomodulators For Cancer Treatment
    • Cancers with New Product Opportunities
    • Bladder Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Head and Neck
    • Kidney
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Multiple Myeloma
    • Neuroblastoma
    • Ovarian Cancer
    • Pancreas
    • Prostate Cancer
    • Cancer Immunomodulator Pipeline
    • Phase III
    • Phase II
    • Phase I
    • Market and Product Launch Forecasts
    • Potential Competitors and Analysis, 2008
  • Chapter Five: Issues And Trends
    • Insurance and Reimbursement Issues
    • Alliances Acquisitions and Licensing Agreements
    • Marketing and Distribution Trends
    • Immunogenicity
    • Future Business Strategies
    • PhytoImmunotherapy
    • Thalidomide Controversy
  • Chapter Six: Total Market Size And Forecast
    • Overview
    • Total Market Size and Forecast
    • Competitive Analysis
  • Chapter Seven: Corporate Profiles Of Current Developers
    • Introduction
    • Amgen, Inc.
    • Berlex Laboratories/Schering AG
    • Chiron Corporation
    • Chugai Pharmaceutical Company, Ltd.
    • Millennium Pharmaceuticals, Inc.
    • OrthoBiotech Products, L.P.
    • Roche
    • Sankyo Company, Ltd.
    • Schering-Plough Corporation
  • Chapter Eight: Corporate Profiles Of Emerging Developers
    • Introduction
    • Celgene Corporation
    • CEL-SCI Corporation
    • Coley Pharmaceutical Group
    • EMD Lexigen
    • Enzon Pharmaceuticals, Inc.
    • Human Genome Sciences, Inc.
    • IDM, SA
    • Lorus Therapeutics Inc.
    • Maxim Pharmaceuticals
    • NeoPharm, Inc.
    • Neurocrine Biosciences, Inc.
    • Onyx Pharmaceuticals, Inc.
    • Peregrine Pharmaceuticals, Inc.
    • Xcyte Therapies, Inc.
    • ZYCOS, Inc.
  • Appendix A: Regulatory Authorities And Research Organizations
  • Appendix B: Company Directory
  • List Of Exhibits
  • Chapter One: Executive Summary
    • Table 1-1: The Total Market for Cancer Immunomodulators 2001-2008
    • Figure 1-1: The Total Market for Cancer Immunomodulators 2001-2008
  • Chapter Two: Introduction
    • Table 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
    • Figure 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
    • Table 2-2: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
    • Figure 2-2: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
    • Table 2-3: World Population by Selected Geographical Region, 2003-2050
    • Figure 2-3: World Population by Selected Geographical Region, 2003-2050
    • Table 2-4: Estimated World Population by Age and Geographical Region, 2003
    • Figure 2-4: Estimated World Population by Age and Geographical Region, 2003
    • Table 2-5: Life Expectancy at Birth by Selected Countries, 2000
    • Table 2-6: United States Life Expectancy at Birth, 1990-2000, and Projections, 2005-2010
    • Figure 2-5: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2000
    • Figure 2-6: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2000
  • Chapter Three: Current Immunomodulators Available For Cancer Treatment
    • Table 3-1: Types of Leukemia
    • Table 3-2: Classification of Non-Hodgkin’s Lymphomas
    • Table 3-3: Malignant Conditions of the Skin
    • Table 3-4: Estimated World and U.S. Incidence and Mortality of Cancers with Current Immunomodulator Treatments (thousands)
    • Figure 3-1: Estimated World Incidence and Mortality of Cancers with Current Immunomodulator Treatment Available
    • Figure 3-2: Estimated U.S. Incidence and Mortality of Cancers with Current Immunomodulator Treatment Available
    • Table 3-5: Current Cancer Immunomodulator Market, 2001-2008 (in millions of dollars at the manufacturers level)
    • Figure 3-3: Current Cancer Immunomodulator Market, 2001-2008
    • Table 3-6: Current Cancer Immunomodulator Market Revenues by Treatment Type, Tumor vs Adjunct, 2003
    • Table 3-7: Current Cancer Immunomodulator Market Leading Suppliers Shares by Market Revenues, 2003
    • Figure 3-4: Current Cancer Immunomodulator Market Leading Suppliers Market Share, 2003
    • Table 3-8: Current Cancer Immunomodulator Market Leading Suppliers Shares by Market Revenues, Estimated 2004
    • Figure 3-5: Current Cancer Immunomodulator Market Leading Suppliers Market Share, Estimated 2004
  • Chapter Four: Emerging Immunomodulators For Cancer Treatment
    • Table 4-1: Types of Leukemia
    • Table 4-2: Types of Primary Lung Cancer
    • Table 4-3: Classification of Non-Hodgkin’s Lymphomas
    • Table 4-4: Malignant Conditions of the Skin
    • Table 4-5: Estimated World Incidence and Mortality of Cancers with Potential Immunomodulators in Development (in thousands)
    • Figure 4-1: Estimated World Incidence and Mortality of Cancers with Emerging Immunomodulator Treatments
    • Figure 4-2: Estimated U.S. Incidence and Mortality of Cancers with Emerging Immunomodulator Treatments
    • Table 4-6: Cancer Immunomodulators in the Pipeline
    • Table 4-7: Emerging Cancer Immunomodulators Market 2004-2008
    • Figure 4-3: Emerging Cancer Immunomodulators Market, 2004-2008
    • Table 4-8: Emerging Cancer Immunomodulators Market by Cancer Type 2004-2008
    • Figure 4-4: Emerging Cancer Immunomodulators Market by Type Revenues and Percent Distribution, 2004-2008
    • Table 4-10: Emerging Cancer Immunomodulators Market Projected Revenues and Market Shares of Leading Developers 2008
    • Figure 4-6: Emerging Cancer Immunomodulators Market Projected Market Shares of Leading Developers 2008
  • Chapter Five: Issues And Trends
    • Table 5-1: Competitive Strategies of Biotech Companies
  • Chapter Six: Total Market Size And Forecast
    • Table 6-1: The Total Market for Cancer Immunomodulators 2001-2008
    • Figure 6-1: The Total Market for Cancer Immunomodulators 2001-2008
    • Table 6-2: The Market for Cancer Immunomodulators by Availability Current vs Emerging 2001-2008
    • Figure 6-2: Cancer Immunomodulator Market Distribution of Revenues by Availability Current vs Emerging 2001-2008
    • Figure 6-3: Distribution of Cancer Immunomodulators Available or in Development by Cancer Type 2003
    • Figure 6-4: Number of Products in Development by Phase and Cancer Type